Flucanol

/ Rafa

See prescribing information for full details.

Systemic candidiasis, cryptococcal infections, including cryptococcal meningitis and subsequent AIDS for prevention of relapse. Dermatomycosis where topical therapy inappropriate due to site, severity or extent of infection, including tinea pedis, tinea cruris, tinea versicolor and candida infections. Oropharyngeal candidiasis, atrophic oral candidiasis with dentures, other candidal mucosal infections. Vaginal candidiasis.

Hypersensitivity to fluconazole and other azoles. Not to be co-administered with cisapride.

Hepatic injury: Patients who develop abnormal liver function tests should be monitored for the development of more severe hepatic injury. Discontinue if clinical signs and symptoms consistent with liver disease develop. The convenience and efficacy of the single dose oral capsule regimen for the treatment of vaginal yeast infections should be weighed against the acceptability of a higher incidence of drug related adverse events versus intravaginal agents.

Anaphylaxis has been reported in rare cases. Headache, nausea, abdominal pain, diarrhea, dyspepsia, dizziness, taste perversion.
See prescribing information for full details.

Coumarin anticoagulants, oral hypoglycemics, hydrochlorothiazide, phenytoin, rifampicin, cyclosporin, theophylline, terfenadine, astemizole, cisapride.

Pregnacy: Should be used in pregnancy only if the potential benefit justifies the possible risk to the fetus.
Lactation: The use by nursing mothers is not recommended.